Pterostilbene is a natural polyphenol compound structurally related to resveratrol, found primarily in blueberries and Pterocarpus marsupium. There is some scientific interest in pterostilbene's potential cardiovascular benefits, largely because of its antioxidant, anti-inflammatory, and lipid-lowering properties observed in preclinical studies. Animal and in vitro studies have shown that pterostilbene may improve lipid profiles by lowering LDL cholesterol and triglycerides while increasing HDL cholesterol. It may also help reduce oxidative stress in vascular tissues and inhibit platelet aggregation, which are mechanisms relevant to the prevention of atherosclerosis and cardiovascular disease.

However, robust human clinical evidence remains limited. A small number of clinical trials suggest that pterostilbene supplementation can modestly reduce blood pressure and improve cholesterol levels, particularly when combined with other agents such as grape extract. These studies are generally small and of short duration, limiting the strength of conclusions that can be drawn. Currently, there is not enough high-quality clinical evidence to recommend pterostilbene as a primary or adjunctive treatment for cardiovascular disease. Its use is based more on promising preclinical results and preliminary human data rather than established, large-scale clinical validation.

In summary, while pterostilbene demonstrates potential for cardiovascular support in preliminary research, the overall strength of evidence is modest, and more rigorous human studies are needed to confirm efficacy and safety for this indication.